Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

Inclusion Criteria:

• A woman of childbearing potential must have a negative urine pregnancy test (beta-human chorionic gonadotropin) at screening and at Week 0

• Before randomization, a woman must be either: a) Not of childbearing potential:premenarchal; postmenopausal (greater than [>] 45 years of age with amenorrhea forat least 12 months or any age with amenorrhea for at least 6 months and a serumfollicle-stimulating hormone level (FSH) >40 International Units Per Liter [IU/L]);permanently sterile (example, tubal occlusion, hysterectomy, bilateralsalpingectomy); or otherwise be incapable of pregnancy, b) Of childbearing potentialand practicing a highly effective method of birth control, consistent with localregulations regarding the use of birth control methods for subjects participating inclinical studies: example, established use of oral, injected or implanted hormonalmethods of contraception; placement of an intrauterine device (IUD) or intrauterinesystem (IUS); barrier methods: condom or occlusive cap (diaphragm or cervical/vaultcaps) plus spermicidal foam/gel/ film/cream/suppository (if available in theirlocale); male partner sterilization (the vasectomized partner should be the solepartner for that participant); true abstinence (when this is in line with thepreferred and usual lifestyle of the participant)

• Agree not to receive a Bacillus Calmette Guerin (BCG) vaccination during the study,or within 12 months after the last administration of study drug

• Have a Psoriasis Area and Severity Index (PASI) greater than or equal to [>=] 12 atscreening and at baseline

• Have an involved body surface area (BSA) >= 10 percent (%) at screening and atbaseline

Exclusion Criteria:

• Has unstable cardiovascular disease, defined as a recent clinical deterioration (eg,unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiachospitalization within the last 3 months

• Has a history of lymphoproliferative disease, including lymphoma; a history ofmonoclonal gammopathy of undetermined significance (MGUS); or signs and symptomssuggestive of possible lymphoproliferative disease, such as lymphadenopathy orsplenomegaly

• Has a transplanted organ (with exception of a corneal transplant >3 months beforethe first administration of study drug)

• Has a nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular)

• Has received any anti-tumor necrosis factor alpha (TNF-alpha) biologic therapywithin 3 months before the first administration of study drug